This bill mandates that retail pharmacies in New Mexico maintain specific stocks of buprenorphine, a medication used to treat opioid use disorder. Non-community-based pharmacies must calculate their minimum daily buprenorphine stocking requirement every thirty days and maintain sufficient stock, including at least three additional prescriptions of different buprenorphine formulations. Community-based pharmacies are required to keep at least one prescription of buprenorphine. The bill also requires wholesale drug distributors to report any instances of denied or delayed orders for buprenorphine from retail pharmacies, along with the reasons for such actions. The data collected will be analyzed by the Department of Health, which will publish biannual reports on access to buprenorphine.

Additionally, the bill outlines penalties for non-compliance, including notices for first and second violations for pharmacies and fines for wholesale distributors after repeated violations. It also includes an appropriation of $1.5 million to increase Medicaid reimbursement rates for buprenorphine prescriptions. The provisions of this act are set to take effect on September 1, 2026.